drugset / Trial / NCT01835899

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution

NCT01835899

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in healthy male volunteers

Timeline

Start
2013-04
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerandomilast Small molecule Oral

Indications

No indication recorded.